Ahmedabad-based Apex Heart Institute (AHI) has introduced robotic-assisted angioplasty system in India for the first time. This move can potentially change the way cardiovascular diseases are treated. Now a robotic arm would conduct angioplasties on cardiac patients with an accuracy of sub one millimetre (mm), as against maximum possible 5-10 mm in case of humans.
In a country that conducts 500,000 angioplasties in a year and an estimated 50 million patients are suffering from coronary artery disease, the move may have significant implications in terms of success rates, patient access to the surgical process. Affordability, however, remains a question as the procedure would cost around Rs 75,000 to 100,000 more than the conventional angioplasty.
The future of the technology, that has taken 12 years to perfect by engineers at US-based Corindus (the heart pumps as against other organs which remain still), lies in extending it to remote location surgeries. This would improve the accessibility to patients and widen the net — an estimated 3.5 million patients need angioplasty in India.
Already, Corindus Vascular Robotics has started working with the Mayo Clinic to launch preclinical studies exploring the use of tele-stenting, a robotic treatment for coronary interventions, which can be operated by physicians in remote locations. The US-based surgical robotics company has recently said that there is a global shortage of percutaneous coronary interventions (PCI) capable operators and tele-stenting could emerge as the solution to take the therapy to rural areas.
Dr Tejas Patel, a Padmashree awardee and a clinician known to have conducted over 100,000 cardiac procedures and interventions, and the chairman and chief interventional cardiologist at AHI have conducted over 50 angioplasties in the last month.
AHI is the first and so far the only clinic in India to commercially introduce the CorPath GRX — a vascular robotic system for coronary artery interventional procedures. It is the first such clinic outside the US. "Only eight centers in the US now have this technology. Outside US, we are the first to have it in India. Cardiac robotic surgeries are more recent as against robotic surgeries of other organs and this is expected to bridge the gap between experienced and inexperienced practitioners," Patel said.
USFDA approved CorPath machine costs around $1.5 million and the system has built in artificial intelligence (AI) which helps cardiologists make better clinical judgements.
Riyaz Desai, managing director of MicroPort India, the sole supplier of CorPath GRX in India said that they have tied up with AHI to provide training to other doctors across India and emerge as the Global Centre of Excellence. They plan to train at least 100 doctors in the first year. Patel has already trained over 5,000 cardiologists on angioplasty or stenting through the wrist artery (called transradial access technique pioneered by him).